Clinical Trial Update: Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects [Phase 2]

View source ↗

Summary

This document reports the completion of the Phase 2 extension study of alvimopan for opioid-induced bowel dysfunction in cancer pain subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Opioid-induced Bowel Dysfunction

Drugs mentioned

• Alvimopan (alvimopan)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Cancer, Bowel Dysfunction | Phase 2 | Status: COMPLETED